Drug Trial Radar · NCT05935358
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Nov 28, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- OctapharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis
Conditions
- Severe Hemophilia A
Interventions
NuwiqDrug
Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall haemostatic efficacyTime frame: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
Locations
18 sites in 11 countries. Site status is shown where the registry gives one.
UT Southwestern Medical Center
Dallas, Texas · Recruiting
University Hospital Centre Zagreb
Zagreb, Croatia · Recruiting
Helsinki University Hospital
Helsinki, Finland · Recruiting
CHU de Nantes Hôtel-Dieu
Nantes, France · Recruiting
CHRU de Tours
Tours, France · Terminated
Vivantes Klinikum im Friedrichshein (KFH)
Berlin, Germany · Terminated
Gerinnungszentrum Rhein-Ruhr
Duisburg, Germany · Recruiting
Universitätsklinikum Hamburg Eppendorf (UKE)
Hamburg, Germany · Recruiting
St. John's Medical College Hospital
Bengaluru, India · Recruiting
Christian Medical College Vellore
Vellore, Tamil Nadu, India · Completed
Azienda Ospedaliera Pugliese Ciaccio
Catanzaro, Italy · Terminated
Azienda Ospedaliero Universitaria Careggi - Centro Emofilia
Florence, Italy · Terminated
Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital
Milan, Italy · Terminated
Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia
Skopje, North Macedonia · Recruiting
Clinical Center for Serbia Belgrade
Belgrade, Serbia · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Terminated
St. James's University Hospital
Leeds, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.